Splicing therapeutics for patients affected by lysosomal storage disorders

In this study, we have used a modified U1 snRNA that completely matches the splice donor site of HGSNAT gene exon 2, which corrected the effect of the common 5’ splice site mutation c.234+1G>A in Mucopolysaccharidosis IIIC. In another approach using an antisense oligonucleotide (AO) we have succe...

ver descrição completa

Detalhes bibliográficos
Autor principal: Matos, Liliana (author)
Outros Autores: Gonçalves, Vânia (author), Canals, Isaac (author), Jordan, Peter (author), Grinberg, Daniel (author), Pérez, Belén (author), Prata, Maria João (author), Alves, Sandra (author)
Formato: conferenceObject
Idioma:eng
Publicado em: 2018
Assuntos:
Lysosomal Storage Disorders
Splicing Therapies
Doenças Genéticas
Texto completo:http://hdl.handle.net/10400.18/5489
País:Portugal
Oai:oai:repositorio.insa.pt:10400.18/5489
Descrição
Resumo:In this study, we have used a modified U1 snRNA that completely matches the splice donor site of HGSNAT gene exon 2, which corrected the effect of the common 5’ splice site mutation c.234+1G>A in Mucopolysaccharidosis IIIC. In another approach using an antisense oligonucleotide (AO) we have succeeded in the correction of the c.66G>A splicing mutation in CSTB gene (Unverricht–Lundborg disease). Besides that, we have performed the functional analysis of some IDS gene splicing mutations (Mucopolysaccharidosis II) and used AOs to exploit an alternative therapy for one of those mutations (c.1122C>T on exon 8).

Registros relacionados